CJC-1295/Ipamorelin (no DAC) – 5mg/5mg

This formulation combines CJC-1295 (No DAC) and Ipamorelin, two growth hormone secretagogues that work through complementary mechanisms. This combination is utilized in in vitro and in vivo experimental models investigating coordinated growth hormone axis signaling and pulsatile release dynamics. In controlled laboratory settings, this compound has been evaluated for its activity across multiple biological systems, including:
• CJC-1295 (No DAC) GHRH Receptor Agonism – examined for its role in stimulating growth hormone releasing hormone receptor pathways and downstream IGF-1 signaling modulation
• Ipamorelin Ghrelin Receptor Activation – investigated for its selective growth hormone secretagogue receptor binding and pulsatile growth hormone release patterns
• Synergistic Receptor Co-Stimulation – studied for the combined amplification of growth hormone axis signaling through dual receptor engagement
• Hypothalamic-Pituitary Axis Modulation – evaluated for coordinated effects on somatotropic signaling networks in preclinical experimental models
This compound continues to serve as a research tool for investigating complementary growth hormone secretagogue mechanisms and their coordinated downstream effects on metabolic and anabolic signaling pathways.